STRATEGIE SANTE

What STRATEGIE SANTE does

Stratégie Santé is a French private limited company (SARL) founded in 1990, headquartered in Versailles, France, providing consulting and advisory services to pharmaceutical companies. Its offering is organized around seven core service pillars: regulatory affairs, pharmaceutical development, outsourced project management, quality and quality audits, advice and coaching, online advice and assistance, and non-clinical/clinical support. The firm engages clients through a consultative, sales-led go-to-market model, with services delivered via direct contact (phone, email, contact forms) and supported by a LinkedIn presence and a weekly newsletter that distributes regulatory news and thought-leadership articles.

The firm operates as a boutique specialist rather than a scaled platform: it holds a registered capital of €51,325, maintains a single Versailles headquarters, has no disclosed subsidiaries, and has not raised external funding. Its core 'technology' is expert human capital — senior regulatory professionals who perform dossier audits, registration strategy, eCTD module writing, API/excipient supplier audits, qualification and validation procedures, and inspection assistance. Since 2015, the firm has been accredited by the French tax authority for Crédit d'Impôt Recherche (CIR) and Crédit d'Impôt Innovation (CII), recognizing its R&D-eligible consulting activity.

Through memberships in the international Regulanet and Pharmaxi networks, Stratégie Santé accesses specialists in more than 90 countries, enabling multi-jurisdictional regulatory engagements that exceed its standalone French footprint. The company monetizes exclusively through professional services fees under non-disclosed pricing, with no software, API, app, or AI-enabled product surface disclosed. Active operating signals include regular publication of regulatory articles through June–July 2026 covering EU MDR, IVDR, ANSM, and pharmaceutical supply chain topics.

Name

STRATEGIE SANTE

Legal name

STRATEGIE SANTE

Website

https://strategiesante.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

1–10 employees

Short description

Stratégie Santé is a French pharmaceutical consulting firm, founded 1990 in Versailles, offering regulatory affairs, pharmaceutical development, quality audits, project management, and coaching services to pharma companies, with international reach via the Regulanet and Pharmaxi networks.

Ownership category

akta.pro rank

Product category

Pharmaceutical Consulting Services

NAICS

Management Consulting Services (54161), Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Regulatory Consulting & Compliance Program Management (FDA/USDA/EFSA) (AFALADAC)

akta.pro secondary industry

Risk, Compliance & Internal Controls Consulting (BPAHACAJ)

Keywords

• Pharmaceutical consulting
• Regulatory affairs
• Quality audits
• Pharmaceutical development
• Clinical research services

Headquarters

HQ city

Versailles

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Consulting Services: Professional consulting services in regulatory affairs, pharmaceutical development, project management, quality audits, and coaching for pharmaceutical companies. Services include regulatory strategy, dossier preparation, audit services, and regulatory maintenance.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

STRATEGIE SANTE is a pharmaceutical consulting firm that advises pharmaceutical companies on regulatory affairs, non-clinical and clinical pharmaceutical development, project management, quality audits, coaching, and online advice. The firm sells expert advisory services rather than products, with a focus on guiding clients through regulatory, development, and quality challenges in the pharmaceutical sector.

Product overview

STRATEGIE SANTE is a consulting firm serving pharmaceutical companies since 1990, offering a comprehensive portfolio of 7 core services organized around regulatory affairs, pharmaceutical development, project management, quality and audits, coaching, and online assistance. The company operates through international networks Regulanet and Pharmaxi, providing access to specialists in over 90 countries. Services are delivered by dedicated project managers and quality specialists, with a complete quality service throughout all stages of product conception and lifecycle.

Differentiator

Problem solved

Functional benefit

Products and services

• Regulatory Affairs Consulting Advisory service guiding pharmaceutical companies through the regulatory landscape, helping them interpret and comply with pharmaceutical regulations affecting drug development and commercialization.
• Pharmaceutical Development Consulting Consulting services supporting non-clinical and clinical pharmaceutical development activities for pharmaceutical clients, providing expert guidance across the development lifecycle.
• Project Management Consulting Project management advisory services for pharmaceutical companies to plan, coordinate, and execute complex development and regulatory projects.
• Quality Audits Quality audit services for pharmaceutical operations, helping clients assess, maintain, and improve quality standards and compliance.
• Coaching and Online Advice Coaching and online advisory services supporting pharmaceutical professionals and teams through development and regulatory challenges.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• RegulanetcoreStrategic or Co-development PartnerInternational regulatory affairs network providing Stratégie Santé with privileged access to specialists in more than 90 countries, enabling the company to support clients with international regulatory needs.
• PharmaxicoreStrategic or Co-development PartnerInternational pharmaceutical consulting network providing Stratégie Santé with privileged access to specialists in more than 90 countries, enabling comprehensive support for pharmaceutical development and regulatory affairs internationally.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Regional players

• LSK Global Pharma Services: Asia-based CRO with regulatory affairs and clinical development services. Comparable in regulatory consulting capability but primarily serves Asia-Pacific sponsors and complements rather than directly contests Stratégie Santé in Europe.

Direct peers

• NDA Group: Regulatory affairs and HTA consultancy serving pharmaceutical and biotech companies across Europe. Directly comparable in regulatory strategy, dossier support, and quality/CMC advisory services to mid-sized pharma clients.
• Voisin Consulting Life Sciences: European regulatory affairs and pharmaceutical development consultancy with a comparable service portfolio spanning regulatory strategy, CMC, and quality. Directly comparable as a specialist pharma regulatory firm competing for similar European mid-market clients.
• PharmaLex: Now part of Cencora, PharmaLex is a global regulatory and pharmacovigilance services provider. Comparable in regulatory affairs, development consulting, and quality services, though operating at significantly greater scale.

Emerging players

• Biopharma Excellence: European pharma regulatory and development consultancy focused on CMC, regulatory strategy, and quality. Comparable niche specialist competing for similar mid-market pharmaceutical regulatory engagements.
• Pharmitt: Boutique European regulatory affairs and pharmacovigilance consultancy. Comparable as a niche regulatory specialist, typically serving small to mid-sized pharma clients across similar European jurisdictions.
• Keyrus Life Science: European consulting firm with a dedicated life sciences practice covering regulatory affairs, clinical operations, and data analytics. Comparable as a multi-disciplinary European pharma consultancy with regulatory depth, though broader in scope.

Broad incumbents

• ICON plc: Global CRO with significant regulatory and pharmacovigilance services post-PRA Health Sciences. Comparable in regulatory consulting but with broader clinical and commercial scope and substantially greater scale.
• IQVIA: Largest global CRO and healthcare data analytics firm with extensive regulatory affairs and quality consulting capabilities. Competes for enterprise regulatory mandates and represents the upper-bound scale competitor to specialist firms like Stratégie Santé.
• Parexel International: Major global CRO offering full-service clinical, regulatory, and market access capabilities. Comparable on the regulatory affairs dimension but operates as a much broader incumbent across the full drug development lifecycle.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/strategie-sante

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STRATEGIE SANTE